专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

AU2014207321A1 Anti-TNF and anti-IL17 combination therapy biomarkers for inflammatory disease 未知
公开(公告)号：AU2014207321A1
公开(公告)日：2015-07-23
申请号：AU2014207321
申请日：2014-01-21
申请人： ABBVIE INC , CUFF CAROLYN A , VOSS JEFFREY W
发明人： VOSS JEFFREY W , CUFF CAROLYN A
IPC分类号： G01N33/68 , G01N33/50
摘要： The invention provides methods for predicting the efficacy of anti-TNF and anti- IL17 combination therapies in the treatment of a subject suffering from inflammatory disease by determining the level CXCL1 and/or CXCL5 markers in a sample derived from the subject.

2. 发明申请

WO9429442A3 TIGHT CONTROL OF GENE EXPRESSION IN EUCARYOTIC CELLS BY TETRACYCLINE-RESPONSIVE PROMOTERS 审中-公开
标题翻译：通过四环素反应促进剂对真核细胞中基因表达的严格控制
公开(公告)号：WO9429442A3
公开(公告)日：1995-02-02
申请号：PCT/US9406734
申请日：1994-06-14
申请人： BASF AG , BUJARD HERMANN , GOSSEN MANFRED , SALFELD JOCHEN G , VOSS JEFFREY W
发明人： BUJARD HERMANN , GOSSEN MANFRED , SALFELD JOCHEN G , VOSS JEFFREY W
IPC分类号： A01K67/027 , A61K48/00 , C07K14/00 , C12N5/08 , C12N5/10 , C12N15/00 , C12N15/09 , C12N15/31 , C12N15/62 , C12N15/63 , C12N15/85 , C12R1/91 , C12N1/15 , C12N1/19 , C12N15/12 , C12N15/90
CPC分类号： A01K67/0275 , A01K2217/05 , A01K2217/075 , C07K2319/09 , C07K2319/61 , C07K2319/71 , C07K2319/80 , C12N15/62 , C12N15/635 , C12N15/85 , C12N2830/006
摘要： Transgenic animals carrying two transgenes, the first coding for a transactivator fusion protein comprising a tet repressor and a polypeptide which directly or indirectly activates in eucaryotic cells, and the second comprising a gene operably linked to a minimal promotor operably linked to at least one tet operator sequence, are disclosed. Isolated DNA molecules (e.g., targeting vectors) for integrating a polynucleotide sequence encoding a transactivator of the invention at a predetermined location within a second target DNA molecule by homologous recombination are also disclosed. Transgenic animals having the DNA molecules of the invention integrated at a predetermined location in a chromosome by homologous recombination are also encompassed by the invention. Methods to regulate the expression of a tet operator linked gene of interest by administering tetracycline or a tetracycline analogue to an animal of the invention are also disclosed. The regulatory system of the invention allows for conditional inactivation or modulation of expression of a gene of interest in a host cell or animal.
摘要翻译：携带两个转基因的转基因动物，第一编码包含直接或间接在真核细胞中活化的tet阻遏物和多肽的反式激活因子融合蛋白，第二编码包含与可操作地连接至少一个tet操纵子的最小启动子可操作地连接的基因序列。还公开了通过同源重组将编码本发明的反式激活物的多核苷酸序列整合到第二靶DNA分子内的预定位置的分离的DNA分子（例如靶向载体）。通过同源重组将具有整合在染色体中预定位置的本发明的DNA分子的转基因动物也包括在本发明中。还公开了通过向本发明的动物施用四环素或四环素类似物来调节所关注的tet操纵子连接基因的表达的方法。本发明的调节系统允许在宿主细胞或动物中有条件地失活或调控感兴趣的基因的表达。

3. 发明申请

WO2015191783A3 BIOMARKERS FOR INFLAMMATORY DISEASE AND METHODS OF USING SAME 审中-公开
标题翻译：用于炎症疾病的生物标志物及其使用方法
公开(公告)号：WO2015191783A3
公开(公告)日：2016-01-14
申请号：PCT/US2015035208
申请日：2015-06-10
申请人： ABBVIE INC , CUFF CAROLYN , RUZEK MELANIE C , VOSS JEFFREY W
发明人： CUFF CAROLYN , RUZEK MELANIE C , VOSS JEFFREY W
IPC分类号： C12Q1/68 , G01N33/564 , G01N33/68
CPC分类号： A61K49/0008 , A61K2039/507 , C07K16/241 , C07K16/244 , C07K2317/31 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158 , G01N33/564 , G01N33/6863 , G01N33/6866 , G01N33/6869 , G01N2333/522 , G01N2333/525 , G01N2333/54 , G01N2800/102 , G01N2800/50 , G01N2800/52 , G01N2800/60 , G01N2800/7095
摘要： The invention provides methods for predicting the efficacy of anti-TNF and anti- IL-17 combination therapies in the treatment of a subject suffering from inflammatory disease by determining the level LIF, CXCL1, CXCL2, CXCL4, CXCL5, CXCL8, CXCL9, CXCL10, CCL2, CCL23, IL-Ιβ, IL-IRa, TNF, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IFNγ, CXCRl, CXCR4, CXCR5, GM-CSF, GM-CSFR, G-CSF, G-CSFR protein or nucleic acid, or a homolog, portion or derivative thereof markers in a sample derived from the subject.
摘要翻译：本发明提供了通过测定LIF，CXCL1，CXCL2，CXCL4，CXCL5，CXCL8，CXCL9，CXCL5，CXCL8，CXCL9，CXCL5， CCL2，CCL23，IL-1β，IL-1Ra，TNF，IL-6，IL-10，IL-17A，IL-17F，IL-21，IL-22，IFNγ，CXCR1，CXCR4，CXCR5，GM-CSF， GM-CSFR，G-CSF，G-CSFR蛋白或核酸，或其衍生自受试者的样品中的同源物，部分或衍生物。

4. 发明申请

WO2015191783A2 BIOMARKERS FOR INFLAMMATORY DISEASE AND METHODS OF USING SAME 审中-公开
标题翻译：用于炎症疾病的生物标志物及其使用方法
公开(公告)号：WO2015191783A2
公开(公告)日：2015-12-17
申请号：PCT/US2015/035208
申请日：2015-06-10
申请人： ABBVIE INC. , CUFF, Carolyn , RUZEK, Melanie, C. , VOSS, Jeffrey, W.
发明人： CUFF, Carolyn , RUZEK, Melanie, C. , VOSS, Jeffrey, W.
IPC分类号： C12Q1/68
CPC分类号： A61K49/0008 , A61K2039/507 , C07K16/241 , C07K16/244 , C07K2317/31 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158 , G01N33/564 , G01N33/6863 , G01N33/6866 , G01N33/6869 , G01N2333/522 , G01N2333/525 , G01N2333/54 , G01N2800/102 , G01N2800/50 , G01N2800/52 , G01N2800/60 , G01N2800/7095
摘要： The invention provides methods for predicting the efficacy of anti-TNF and anti- IL-17 combination therapies in the treatment of a subject suffering from inflammatory disease by determining the level LIF, CXCL1, CXCL2, CXCL4, CXCL5, CXCL8, CXCL9, CXCL10, CCL2, CCL23, IL-Ιβ, IL-IRa, TNF, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, IFNγ, CXCRl, CXCR4, CXCR5, GM-CSF, GM-CSFR, G-CSF, G-CSFR protein or nucleic acid, or a homolog, portion or derivative thereof markers in a sample derived from the subject.
摘要翻译：本发明提供了通过测定LIF，CXCL1，CXCL2，CXCL4，CXCL5，CXCL8，CXCL9，CXCL5，CXCL8，CXCL9，CXCL5， CCL2，CCL23，IL-1β，IL-1Ra，TNF，IL-6，IL-10，IL-17A，IL-17F，IL-21，IL-22，IFNγ，CXCR1，CXCR4，CXCR5，GM-CSF， GM-CSFR，G-CSF，G-CSFR蛋白或核酸，或其衍生自受试者的样品中的同源物，部分或衍生物。

5. 发明申请

WO2014113804A9 ANTI-TNF AND ANTI-IL17 COMBINATION THERAPY BIOMARKERS FOR INFLAMMATORY DISEASE 审中-公开
公开(公告)号：WO2014113804A9
公开(公告)日：2014-07-24
申请号：PCT/US2014/012364
申请日：2014-01-21
申请人： ABBVIE INC. , VOSS, Jeffrey, W. , CUFF, Carolyn, A.
发明人： VOSS, Jeffrey, W. , CUFF, Carolyn, A.
IPC分类号： G01N33/68 , G01N33/50
摘要： The invention provides methods for predicting the efficacy of anti-TNF and anti- IL17 combination therapies in the treatment of a subject suffering from inflammatory disease by determining the level CXCL1 and/or CXCL5 markers in a sample derived from the subject.

6. 发明申请

WO2014113804A1 ANTI-TNF AND ANTI-IL17 COMBINATION THERAPY BIOMARKERS FOR INFLAMMATORY DISEASE 审中-公开
标题翻译：抗TNF和抗IL17联合治疗炎症性疾病的生物标志物
公开(公告)号：WO2014113804A1
公开(公告)日：2014-07-24
申请号：PCT/US2014012364
申请日：2014-01-21
申请人： ABBVIE INC , VOSS JEFFREY W , CUFF CAROLYN A
发明人： VOSS JEFFREY W , CUFF CAROLYN A
IPC分类号： G01N33/68 , G01N33/50
CPC分类号： G01N33/6863 , A61K39/3955 , C12Q1/6883 , G01N2333/522 , G01N2333/525 , G01N2333/54 , G01N2800/52
摘要： The invention provides methods for predicting the efficacy of anti-TNF and anti- IL17 combination therapies in the treatment of a subject suffering from inflammatory disease by determining the level CXCL1 and/or CXCL5 markers in a sample derived from the subject.
摘要翻译：本发明提供了通过确定源自受试者的样品中的CXCL1和/或CXCL5水平的水平来预测抗TNF和抗IL17联合疗法在治疗患有炎性疾病的受试者中的功效的方法。

7. 发明申请

WO2009152133A1 NOVEL TRICYCLIC COMPOUNDS 审中-公开
标题翻译：新型三聚体化合物
公开(公告)号：WO2009152133A1
公开(公告)日：2009-12-17
申请号：PCT/US2009/046714
申请日：2009-06-09
申请人： ABBOTT LABORATORIES , WISHART, Neil , ARGIRIADI, Maria, A. , CALDERWOOD, David, J. , ERICSSON, Anna, M. , FIAMENGO, Bryan, A. , FRANK, Kristine, E. , FRIEDMAN, Michael , GEORGE, Dawn, M. , GOEDKEN, Eric, R. , JOSEPHSOHN, Nathan, S. , LI, Biqin, C. , MORYTKO, Michael, J. , STEWART, Kent, D. , VOSS, Jeffrey, W. , WALLACE, Grier, A. , WANG, Lu , WOLLER, Kevin, R.
发明人： WISHART, Neil , ARGIRIADI, Maria, A. , CALDERWOOD, David, J. , ERICSSON, Anna, M. , FIAMENGO, Bryan, A. , FRANK, Kristine, E. , FRIEDMAN, Michael , GEORGE, Dawn, M. , GOEDKEN, Eric, R. , JOSEPHSOHN, Nathan, S. , LI, Biqin, C. , MORYTKO, Michael, J. , STEWART, Kent, D. , VOSS, Jeffrey, W. , WALLACE, Grier, A. , WANG, Lu , WOLLER, Kevin, R.
IPC分类号： A01N43/42
CPC分类号： C07D487/14 , C07D498/14 , C07D513/14
摘要： The invention provides a compound of Formula (I), pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
摘要翻译：本发明提供式（I）的化合物，其药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。本发明的化合物可用于治疗免疫学和肿瘤学病症。

8. 发明申请

WO2005047307A3 IL-18 BINDING PROTEINS 审中-公开
标题翻译： IL-18结合蛋白
公开(公告)号：WO2005047307A3
公开(公告)日：2006-08-31
申请号：PCT/US2004037971
申请日：2004-11-12
申请人： ABBOTT LAB , GHAYUR TARIQ , LABKOVSKY BORIS , VOSS JEFFREY W , GREEN LARRY , BABCOOK JOHN , JIA XIAO-CHI , WIELER JAMES , KANG JASPAL SINGH , HEDBERG BRAD
发明人： GHAYUR TARIQ , LABKOVSKY BORIS , VOSS JEFFREY W , GREEN LARRY , BABCOOK JOHN , JIA XIAO-CHI , WIELER JAMES , KANG JASPAL SINGH , HEDBERG BRAD
IPC分类号： C07K16/00 , A61K39/395 , C07H21/04 , C07K16/24 , C12N15/00 , G01N33/53 , G01N33/68
CPC分类号： G01N33/6869 , A61K2039/505 , C07K16/244 , C07K2317/33 , C07K2317/52 , C07K2317/55 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
摘要翻译：本发明包括IL-18结合蛋白，特别是结合人白细胞介素-18（hIL-18）的抗体。具体地，本发明涉及完全是人抗体的抗体。优选的抗体对hIL-18具有高亲和力和/或在体外和体内中和hIL-18活性。本发明的抗体可以是全长抗体或其抗原结合部分。还提供了制备方法和使用本发明抗体的方法。本发明的抗体或抗体部分可用于检测hIL-18和抑制hIL-18活性，例如在患有hIL-18活性有害的病症的人类受试者中。

9. 发明申请

WO2005047307A2 IL-18 BINDING PROTEINS 审中-公开
标题翻译： IL-18结合蛋白
公开(公告)号：WO2005047307A2
公开(公告)日：2005-05-26
申请号：PCT/US2004/037971
申请日：2004-11-12
申请人： ABBOTT LABORATORIES , GHAYUR, Tariq , LABKOVSKY, Boris , VOSS, Jeffrey W., , GREEN, Larry , BABCOOK, John , JIA, Xiao-chi , WIELER, James , KANG, Jaspal Singh , HEDBERG, Brad
发明人： GHAYUR, Tariq , LABKOVSKY, Boris , VOSS, Jeffrey W., , GREEN, Larry , BABCOOK, John , JIA, Xiao-chi , WIELER, James , KANG, Jaspal Singh , HEDBERG, Brad
IPC分类号： C07K
CPC分类号： G01N33/6869 , A61K2039/505 , C07K16/244 , C07K2317/33 , C07K2317/52 , C07K2317/55 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94 , Y02A50/407
摘要： The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
摘要翻译：本发明包括IL-18结合蛋白，特别是结合人白细胞介素-18（hIL-18）的抗体。具体地，本发明涉及完全是人抗体的抗体。优选的抗体对hIL-18具有高亲和力和/或在体外和体内中和hIL-18活性。本发明的抗体可以是全长抗体或其抗原结合部分。还提供了制备方法和使用本发明抗体的方法。本发明的抗体或抗体部分可用于检测hIL-18和抑制hIL-18活性，例如在患有hIL-18活性有害的病症的人类受试者中。

10. 发明申请

WO1996008246A2 INDUCERS OF GAMMA GLOBIN GENE EXPRESSION AND SCREENING ASSAYS THEREFOR 审中-公开
标题翻译： GAMMA GLOBIN基因表达和筛选测定的诱导剂
公开(公告)号：WO1996008246A2
公开(公告)日：1996-03-21
申请号：PCT/US1995011823
申请日：1995-09-15
申请人： BASF AKTIENGESELLSCHAFT , VOSS, Jeffrey, W. , CARON, Connie
发明人： BASF AKTIENGESELLSCHAFT
IPC分类号： A61K31/19
CPC分类号： A61K31/19 , C12Q1/6897 , Y02A50/411
摘要： Methods for stimulating gamma globin gene expression in a mammalian cell comprising contacting the cell with a compound selected from valeric acid and certain isomers, derivatives or salts thereof, including isovaleric acid, 4-pentynoic acid and methylthioacetic acid, or an inhibitor of a short chain fatty acyl CoA dehydrogenase, or an activator of protein kinase C are disclosed. The methods of the invention are particularly useful for ameliorating beta -globin disorders, such as sickle cell anemia or beta -thalassemia. The method of the invention can also be used to prevent or ameliorate malaria in a mammal. The compounds of the invention can also be used to stimulate differentiation of a cell. Pharmaceutical compositions of the acive compounds of the invention are also disclosed. Screening assays for identifying agents that stimulate gamma globin gene expression in an erythroid cell, stimulate cell differentiation or stimulate transport of a short chain fatty acid, or derivative or salt thereof, into cells are also disclosed.
摘要翻译：用于刺激哺乳动物细胞中的γ珠蛋白基因表达的方法，包括使细胞与选自戊酸和某些异构体，其衍生物或其盐的化合物，包括异戊酸，4-戊炔酸和甲基硫代乙酸或短链的抑制剂接触脂肪酰辅酶A脱氢酶或蛋白激酶C的活化剂。本发明的方法特别可用于改善β-球蛋白病症，例如镰状细胞性贫血或β-地贫。本发明的方法也可用于预防或改善哺乳动物的疟疾。本发明的化合物也可用于刺激细胞的分化。还公开了本发明的酸性化合物的药物组合物。还公开了用于鉴定刺激红细胞中的γ珠蛋白基因表达，刺激细胞分化或刺激短链脂肪酸或其衍生物或其盐转运到细胞中的药剂的筛选试验。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式